5.73
price up icon1.96%   0.11
after-market Handel nachbörslich: 5.63 -0.10 -1.75%
loading
Schlusskurs vom Vortag:
$5.62
Offen:
$5.41
24-Stunden-Volumen:
1.46M
Relative Volume:
3.16
Marktkapitalisierung:
$192.71M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-3.6266
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
+60.50%
1M Leistung:
+128.29%
6M Leistung:
+72.59%
1J Leistung:
-26.06%
1-Tages-Spanne:
Value
$5.10
$5.74
1-Wochen-Bereich:
Value
$3.54
$6.15
52-Wochen-Spanne:
Value
$2.315
$10.13

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
Firmenname
Fulcrum Therapeutics Inc
Name
Telefon
617-651-8851
Name
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Mitarbeiter
45
Name
Twitter
@fulcrumtx
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
FULC's Discussions on Twitter

Vergleichen Sie FULC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FULC
Fulcrum Therapeutics Inc
5.73 192.71M 2.81M -97.34M -91.47M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.19 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
603.58 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.65 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
273.55 32.98B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.16 26.89B 3.81B -644.79M -669.77M -6.24

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-13 Herabstufung H.C. Wainwright Buy → Neutral
2024-09-12 Herabstufung BofA Securities Neutral → Underperform
2024-09-12 Herabstufung Cantor Fitzgerald Overweight → Neutral
2024-09-12 Herabstufung Leerink Partners Outperform → Market Perform
2024-09-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-09-12 Herabstufung Stifel Buy → Hold
2024-09-09 Hochstufung BofA Securities Underperform → Neutral
2024-05-20 Eingeleitet Cantor Fitzgerald Overweight
2024-03-13 Eingeleitet RBC Capital Mkts Outperform
2023-09-25 Eingeleitet Goldman Neutral
2023-08-23 Hochstufung H.C. Wainwright Neutral → Buy
2023-08-22 Hochstufung Stifel Hold → Buy
2023-05-04 Herabstufung Goldman Buy → Neutral
2023-03-10 Herabstufung Credit Suisse Outperform → Neutral
2023-03-10 Herabstufung H.C. Wainwright Buy → Neutral
2023-03-09 Herabstufung Stifel Buy → Hold
2023-02-28 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-02-24 Herabstufung BofA Securities Neutral → Underperform
2022-11-15 Eingeleitet Goldman Buy
2022-03-08 Eingeleitet Oppenheimer Outperform
2022-03-03 Hochstufung BofA Securities Underperform → Neutral
2021-08-11 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-22 Eingeleitet Credit Suisse Outperform
2021-03-02 Eingeleitet Stifel Buy
2020-10-16 Eingeleitet Piper Sandler Overweight
2020-08-12 Herabstufung BofA Securities Neutral → Underperform
2020-08-12 Bestätigt H.C. Wainwright Buy
2020-08-12 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-06-19 Herabstufung BofA/Merrill Buy → Neutral
2020-06-17 Eingeleitet BTIG Research Buy
2019-10-03 Eingeleitet H.C. Wainwright Buy
2019-08-12 Eingeleitet BofA/Merrill Buy
Alle ansehen

Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten

pulisher
May 03, 2025

Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025 - MSN

May 03, 2025
pulisher
May 02, 2025

Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - Sete News

May 02, 2025
pulisher
May 02, 2025

Fulcrum Therapeutics Inc (FULC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics’ Positive Earnings Call Highlights - TipRanks

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss By Investing.com - Investing.com South Africa

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Inc [FULC] stock for 1,831 USD was sold by Tourangeau Greg - knoxdaily.com

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Inc Q1 2025 Earnings: EPS of -$0.28 Beats E - GuruFocus

May 01, 2025
pulisher
May 01, 2025

FULC Achieves Milestone in Sickle Cell Disease Treatment Development | FULC Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

FULC Financial Update: Cash Position Shifts in Early 2025 | FULC Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics (FULC) Target Price Adjusted Amid Strong Ca - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Are Fulcrum Therapeutics Inc’shares a good deal? - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss - Investing.com

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 2c - StreetInsider

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView

May 01, 2025
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 26, 2025

Geode Capital Management LLC Sells 26,347 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Daily Progress: Fulcrum Therapeutics Inc (FULC) Drop -10.27, Closing at 3.32 - DWinneX

Apr 25, 2025
pulisher
Apr 24, 2025

Fulcrum Therapeutics Inc [NASDAQ: FULC] Sees Decrease in Stock Value - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Fulcrum Therapeutics to Release First Quarter 2025 Financial Results on May 1, 2025 - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET - The Manila Times

Apr 24, 2025
pulisher
Apr 24, 2025

Earnings Call Alert: Rare Disease Developer Fulcrum Therapeutics Sets Q1 2025 Results Date - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

Investing in Fulcrum Therapeutics Inc (FULC) might be a great opportunity, but the stock is a bit overvalued - uspostnews.com

Apr 23, 2025
pulisher
Apr 22, 2025

Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $8.63 - Defense World

Apr 22, 2025
pulisher
Apr 14, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Wellington Management Group LLP - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

American Century Companies Inc. Increases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 11, 2025
pulisher
Apr 08, 2025

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance

Apr 08, 2025
pulisher
Apr 08, 2025

Fulcrum Therapeutics, Inc. (FULC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 07, 2025

Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 04, 2025

Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry - simplywall.st

Apr 04, 2025
pulisher
Apr 01, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.77 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.77 By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Mar 29, 2025

Charles Schwab Investment Management Inc. Lowers Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Fulcrum Sheds Investor Suit Over Blood Treatment Trial Safety - Bloomberg Law News

Mar 28, 2025
pulisher
Mar 28, 2025

Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $8.63 - Defense World

Mar 28, 2025
pulisher
Mar 16, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FULC - Business Wire

Mar 16, 2025
pulisher
Mar 11, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.85 By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.85 - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Fulcrum Therapeutics at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK

Mar 11, 2025

Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
Kapitalisierung:     |  Volumen (24h):